Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin

Clinical Cancer Research

Volumn 5, Issue 4, 1999, Pages 767-774

  Rowinsky, Eric K ^a,e   Jiroutek, Micheal ^b   Bonomi, Philip ^c   Johnson, David ^d   Baker, Sharyn D ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PACLITAXEL; TREATMENT OUTCOME;

EID: 0032905998     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Rowinsky, E. K., and Donehower, R. C. Drug therapy: paclitaxel (Taxol). N. Engl. J. Med., 332: 1004-1114, 1995.
2. Evans, W. E., Relling, M. V., Rodman, J. H., Crom, W. R., Boyett, J. M., and Pui, C. H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med., 338: 499-505, 1998.
3. Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly S., Bunell, M, Boxall, F. E., Siddik, Z. H., Judson, I. R., and Gore, M. E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 7: 1748-1756, 1989.
4. Jodrell, D. I., Egorin, M. J., Canetta, R. M., Langenberg, P., Goldbloom, E. P., Burroughs J. N., Goodlow, J. N., Tan, S., and Wiltshaw, E. Relationships between carboplatin exposure and tumour response in patients with ovarian cancer. J. Clin. Oncol., 10: 520-528, 1992.
5. Rowinsky, E. K. The taxanes: dosing and scheduling considerations. Oncology, 11 (Suppl. 2): 1-13, 1997.
6. Arbuck, S. G., Canetta, R., Onetto, N., and Christian, M. Current dosage and scheduling issues in the development of paclitaxel (Taxol). Semin. Oncol., 4 (Suppl. 3): 31-39, 1993.
7. Arbuck, S. A., and Blaylock, B. Dose and schedule issues. In: W. P. McGuire and E. K. Rowinsky (eds.), Paclitaxel in Cancer Treatment, pp. 151-173. New York: Marcel Dekker, 1995.
8. Rowinsky, E, K., Donehower, R. C., Jones, R. J., and Tucker, R. W. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res., 48: 4093-4100, 1988.
9. Schiff, P. B., and Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77: 1561-1565, 1970.
10. Bhalla, K., Ibrado, A. M., Tourkina, E., Tang, C., Mahoney, M. E., and Huang, Y. Taxol induces intranucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia (Baltimore), 7: 563-568, 1993.
11. Lopes, N. M., Adams, E. G., Pitts, T. W., and Bhuyan, B. K. Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol., 32: 235-242, 1993.
12. Helson, L., Helson, C., Malik, S., Ainsworth, S., and Mangiardi, J. A saturation threshold for Taxol cytotoxicity in human glial and neuroblastoma cells. Anti-Cancer Drugs, 4: 487-490, 1993.
13. Liebmann, J. E., Cook, J. A., Lipschultz, C., Teague, D., Fisher, J., and Mitchell, J. B. Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br. J. Cancer, 68: 1104-1109, 1993.
14. Georgiadis, M. S., Russell, E., and Johnson, B. E. Prolonging the exposure of human lung cancer cell lines to paclitaxel increases the cytotoxicity. Proc. Int. Assoc. Study Lung Cancer, 11: 95, 1994.
15. Figg, W. D., Thibault, A., McCall, N. A., Cooper, M. R., Kohn, E. C., and Myers, C. E. The in vitro activity of Taxol on three hormone refractory prostate cancer cell lines, PC3, DU145, and PC3M. Proc. Am. Assoc. Cancer Res., 35: 431, 1994.
16. Nabholtz, J-M., Gelmon, K., Bontenbal, M., Spielmann, M., Catimel, G., Conte, P., Klaassen, U., Namer, M., Bonneterre, J., Fumoleau, P., and Winograd, B. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J. Clin. Oncol., 14: 1858-1867, 1996.
17. Eisenhauer, E., ten Bokkel Huinink, W., Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E. L., Kerr, I., Vermorken, J. B., Buser, K., Colombo, N., Bacon, M., Santabárbara, P., Onetto, N., Winograd, B., and Canetta, R. European-Canadian randomized trial of Taxol in relapsed ovarian cancer: high versus low dose and long versus short infusion. J. Clin. Oncol., 12: 2654-2666, 1994.
18. Omura, G. A., Brady, M. F., Delmore, J. E., Long, H. J., Long, H. J., Look, K. Y., Averette, H. E., Wadler, S., and Spiegel, G. A randomized trial of paclitaxel at 2 dose levels and Filgrastim (G; G-CSF) at 2 dose levels in platinum pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCTTG and ECOG study. Proc. Am. Soc. Clin. Oncol., 15: 280, 1996.
19. Bonomi, P., Kim, K., Chang, A., and Johnson, D. Phase III trial comparing etoposide-cisplatin versus Taxol with cisplatin-granulocytecolony-stimulating factor versus Taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Group trial. Proc. Am. Soc. Clin. Oncol., 15: 382, 1996.
20. Forastiere, A. A., Leong, T., Murphy, B., Rowinsky, E., DeConti, R., Karp, D., and Adams, G. A Phase III trial of high dose paclitaxel + cisplatin + G-CSF versus low-dose paclitaxel + cisplatin in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. Proc. Am. Soc. Clin. Oncol., 16: 384, 1997.
21. Mamounas, E., Brown, A., Smith, R., Lembersky, B., Fisher, B., Wickerham. D. L., Wolmark, N., Atkins, J., Shibata, H., Baez, L., DeFusco, P., Davila, E., Thirlwell, M., Bearden, J., Tipping, S., and Scholnik, A. Effect of Taxol duration of infusion in advanced breast cancer (ABC): results from NSABP B-26 trial comparing 3-to 24-hour infusion of high-dose Taxol. Proc. Am. Soc. Clin. Oncol., 17: 101a, 1998.
22. Winer, E., Berry, D., Duggan, D., Henderson, I. C., Cirrincione, C., Cooper, R., and Norton, L. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: results from CALGB 9342. Proc. Am. Soc. Clin. Oncol., 17: 101a, 1998.
23. Rowinsky, E. K. Pharmacology and metabolism. In: W. G. McGuire and E. K. Rowinsky (eds.), Paclitaxel in Cancer Treatment, pp. 91-120. New York: Marcel Dekker, 1995.
24. Rowinsky, E. K., Wright, M., Monsarrat, B., Lesser, G. J., and Donehower, R. C. Taxol: pharmacology, metabolism, and clinical implications. Cancer Surv., 17: 283-304, 1993.
25. Huizing, M. T., Keung, A. C. F., Rosing, H., van der Kuij, V., ten Bokkel Huinink, W. W., Mangjes, I. M., Dubbelman, A. C., Pinedo, H. M., and Beijnen, J. H. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum pretreated ovarian cancer patients. J. Clin. Oncol., 11: 2127-2135, 1993.
26. Ohtsu, T., Sasaki, Y., Tamura, T., Miyata, Y., Nakanomyo. H., Nishiwaki, Y., and Saijo, N. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin. Cancer Res., 1: 599-606, 1995.
27. Gianni, L., Kearns, C., Gianni, A., Capri, G., Vigano, L., Lacatell, A., Bonnadonna, G., and Egorin, M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol., 13: 180-189, 1995.
28. Sonnichsen, D., Hurwitz, C., Pratt, C., and Relling, M. C. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J. Clin. Oncol., 12: 532-538, 1994.
29. Longnecker, S. M., Donehower, R. C., Cates, A., Chen, T., Brundrett, R. B., Grochow, L. B., Ettinger, D. S., and Colvin, M. High performance liquid chromatographic assay for paclitaxel (NSC 125973) in human plasma and urine pharmacokinetics in a Phase I trial. Cancer Treat. Rep., 71: 53-59, 1981.
30. Rowinsky, E. K., Chaudhry, V., Forastiere, A. A., Sartorius, S. E., Ettinger, D. S., Grochow, L. B., Lubejko, B. G., Cornblath, D. R., and Donehower, R. C. A Phase I and pharmacologic study of Taxol and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin. Oncol, 11: 2010-2020, 1993.
31. Chang, A. T., Kim, L., Glick, J., Karp, D., and Johnson, D. Phase II study of Taxol, merbaraone, and piroxantrone in stage IV non-small cell lung cancer. The Eastern Cooperative Group results. J. Natl. Cancer Inst. (Bethesda), 85: 388-394, 1993.
32. Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., and Carbone, P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol., 5: 649-655, 1982.
33. Weiss, M. Model-independent assessment of accumulation kinetics based on moments of drug disposition waves. Eur. J. Clin. Pharmacol., 27: 355-358, 1984.
34. Rowinsky, E. K., Gilbert, M., McGuire, W. P., Ettinger, D. S., Forastiere, A., Grochow, L. B., Clark, B., Sartorius, S. E., Cornblath, D. R., Hendricks, C. B., and Donehower, R. C. Sequences of Taxol and cisplatin: a Phase I and pharmacologic study. J. Clin. Oncol., 9: 1692-1703, 1991.
35. SAS Institute. SAS/STAT Users Guide, Version 6, Ed. 4, Vol. 2. Cary, NC: SAS Institute Inc., 1992.
36. SAS Institute. Changes and Enhancements, Release 6.07, SAS Technical Report P-229, SAT/STAT Software. Cary, NC: SAS Institute Inc., 1992.
37. Rowinsky, E. K., Chaudhry, V., Cornblath, D. R., and Donehower, R. C. The neurotoxicity of Taxol. Monogr. Natl. Cancer Inst., 15: 107-115, 1993.
38. Rowinsky, E. K., Burke, P. J., Karpe, J. E., and Tucker, R. W. Phase I and pharmacodynamic study of Taxol in refractory acute leukemia. Cancer Res., 49: 4640-4647, 1989.
39. Rowinsky, E. K., Mackey, M. K., and Goodman, S. N. Meta analysis of paclitaxel dose-response and dose-intensity in recurrent or refractory ovarian cancer. Proc. Am. Soc. Clin. Oncol., 15: 284, 1996.
40. 3H]paclitaxel in rats: a quantitative autoradiographic study. Cancer Chemother. Pharmacol., 34: 173-178, 1995.
41. Walle, T., Walle, U. K., Kumar, G. N., and Bhalla, K. N. Taxol metabolism and disposition in cancer patients. Drug Metab. Disp., 23: 506-512, 1995.